140 related articles for article (PubMed ID: 31796515)
1. The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.
Croce S; Lesluyes T; Valle C; M'Hamdi L; Thébault N; Pérot G; Stoeckle E; Noël JC; Fontanges Q; Devouassoux-Shisheboran M; Querleu D; Guyon F; Floquet A; Chakiba C; Mayeur L; Rebier F; MacGrogan GM; Soubeyran I; Le Guellec S; Chibon F
Clin Cancer Res; 2020 Feb; 26(4):855-861. PubMed ID: 31796515
[TBL] [Abstract][Full Text] [Related]
2. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
[TBL] [Abstract][Full Text] [Related]
4. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
5. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.
Italiano A; Lagarde P; Brulard C; Terrier P; Laë M; Marques B; Ranchere-Vince D; Michels JJ; Trassard M; Cioffi A; Piperno-Neumann S; Chevreau C; Blay JY; Delcambre C; Isambert N; Penel N; Bay JO; Bonvalot S; Le Cesne A; Coindre JM; Chibon F
Clin Cancer Res; 2013 Mar; 19(5):1190-6. PubMed ID: 23329812
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
[TBL] [Abstract][Full Text] [Related]
7. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
[TBL] [Abstract][Full Text] [Related]
9. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.
Lee CH; Roh JW; Choi JS; Kang S; Park IA; Chung HH; Jeon YT; Kim JW; Park NH; Kang SB; Song YS
Int J Gynecol Cancer; 2011 May; 21(4):668-72. PubMed ID: 21412163
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
15. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Apr; 35(4):2229-34. PubMed ID: 25862883
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in early-stage leiomyosarcoma of the uterus.
Pelmus M; Penault-Llorca F; Guillou L; Collin F; Bertrand G; Trassard M; Leroux A; Floquet A; Stoeckle E; Thomas L; MacGrogan G
Int J Gynecol Cancer; 2009 Apr; 19(3):385-90. PubMed ID: 19407564
[TBL] [Abstract][Full Text] [Related]
18. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
20. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
